ClinicalTrials.gg
Not yet recruitingNCT06679647Updated Nov 7, 2024

Acceptability, Usability and Preliminary Effectiveness of ChatGPT in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults in Hong Kong

An interventional study of Access to a trained ChatGPT in Behavior Change Interventions, sponsored by Chinese University of Hong Kong. Not yet recruiting. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

In this project, we will train a ChatGPT to provide real-time answers to questions related to the SIV for older adults in Hong Kong.

This study aims to evaluate the usability, acceptability, and preliminary effectiveness of the ChatGPT among 50 community-living people aged 65 years and above in Hong Kong.

The primary objectives are to evaluate the usability and acceptability (including the extent of usage and subjective experiences of behavioural, cognitive, and affective engagement) of the ChatGPT at the end of the 4-week intervention period (T1).

The secondary objectives are to evaluate the following conditions measured at T1, as compared to those measured at baseline (T0):

  1. Self-reported uptake of SIV in the past month.
  2. Changes in behavioural intention to receive SIV for the approaching flu season.
  3. Changes in knowledge and attitudes related to SIV.
02

Conditions studied

  • Behavior Change Interventions
03

In context

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,446 studies on the registry; 467 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥65 years;
  • Possession of a Hong Kong ID;
  • Able to speak and comprehend Cantonese;
  • Have a smartphone with internet access;
  • Have not taken SIV for the approaching flu season.

Exclusion criteria

Exclusion Criteria:

  • With diagnosis of cognitive impairment or dementia;
  • Either blindness or deafness;
  • With known contraindications to the SIV as indicated by the Hong Kong Centre for Health Protection
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    ChatGPT group

    Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.

    Behavioral: Access to a trained ChatGPT

Interventions

  • BehavioralAccess to a trained ChatGPT

    Participants will be invited to use a trained ChatGPT which answers questions related to seasonal influenza vaccination. The functions can be used repeatedly throughout the intervention period (4 weeks), and participants will be free to spend as much time as they want on such functions.

06

What researchers measure

Primary outcomes

  1. Perceived usability

    Perceived usability assessed by the validated Chinese version of the 10-item Perceived Usability Scale (SUS)

    Time frame: 1 month

  2. Extent of usage documented by the ChatGPT

    Extent of usage documented by the ChatGPT

    Time frame: 1 month

  3. Subjective experiences related to behavioural, cognitive, and affective engagement

    Subjective experiences related to behavioural, cognitive, and affective engagement measured by the validated Twente Engagement with eHealth Technologies Scale (TWEETS)

    Time frame: 1 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Wang Z, Tsang TH, Yu FY, Fang Y, Chen S, Sun F, Mo PKH, Wong KC. Effectiveness, Usability, and Acceptability of ChatGPT With Retrieval-Augmented Generation (SIV-ChatGPT) in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults: Quasi-Experimental Study. J Med Internet Res. 2025 Sep 8;27:e76849. doi: 10.2196/76849. PubMed 40921067 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06679647
Responsible party
Zixin Wang (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Nov 7, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Nov 7, 2024

Study contacts

Zixin Wang, PhD
Contact
wangzx@cuhk.edu.hk
+852 22528740
Zixin Wang, PhD
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion